Complement interactions with amyloid β1–42: A nidus for inflammation in AD brains
暂无分享,去创建一个
[1] M. Emmerling,et al. Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide. , 1997, Immunopharmacology.
[2] H. Wiśniewski,et al. The “Nonamyloidogenic” p3 Fragment (Amyloid β17-42) Is a Major Constituent of Down's Syndrome Cerebellar Preamyloid* , 1996, The Journal of Biological Chemistry.
[3] Marla Gearing,et al. Aβ 40 is a major form of β-amyloid in nonhuman primates , 1996, Neurobiology of Aging.
[4] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[5] L. Lue,et al. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. , 1996, Journal of neuropathology and experimental neurology.
[6] A. Roher,et al. Specific Domains of β-Amyloid from Alzheimer Plaque Elicit Neuron Killing in Human Microglia , 1996, The Journal of Neuroscience.
[7] Douglas Walker,et al. Inflammation and Alzheimer's disease pathogenesis , 1996, Neurobiology of Aging.
[8] R. Veerhuis,et al. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease , 1996, Neurobiology of Aging.
[9] Brian J Cummings,et al. Localization and Cell Association of C1q in Alzheimer's Disease Brain , 1996, Experimental Neurology.
[10] T. Iwatsubo,et al. Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[11] P. Gasque,et al. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. , 1995, Journal of immunology.
[12] D. Mann,et al. Microglial cells and amyloid ? protein (A?) deposition: association with A?40-containing plaques , 1995 .
[13] S. Whittemore,et al. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia , 1995, Journal of Neuroimmunology.
[14] P. Gasque,et al. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. , 1995, Journal of immunology.
[15] D. Walker,et al. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains , 1995, Journal of neuroscience research.
[16] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[17] C. Glabe,et al. Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation. , 1994, The Journal of biological chemistry.
[18] David A. Willoughby,et al. Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxinsin vivo andin vitro , 1994, Neuroscience.
[19] L. Thal,et al. Lack of long-term effects after β-amyloid protein injections in rat brain , 1994, Neurobiology of Aging.
[20] C. Cotman,et al. beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. , 1994, Journal of immunology.
[21] M. Ball,et al. Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. , 1994, The Journal of biological chemistry.
[22] M J Ball,et al. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[23] L. Lue,et al. Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. , 1993, Brain research. Molecular brain research.
[24] P. Mcgeer,et al. Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[25] D. Selkoe,et al. Synthetic amyloid β-protein fails to produce specific neurotoxicity in monkey cerebral cortex , 1992, Neurobiology of Aging.
[26] I. Lieberburg,et al. Lack of alzheimer pathology after β-amyloid protein injections in rat brain , 1992, Neurobiology of Aging.
[27] G. Cole,et al. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. , 1992, The American journal of pathology.
[28] H. Fraser,et al. Cerebral amyloid plaques in Alzheimer’s disease but not in scrapie-affected mice are closely associated with a local inflammatory process , 1991, Virchows Archiv. B, Cell pathology including molecular pathology.
[29] G. Cole,et al. Effects of injected Alzheimer beta-amyloid cores in rat brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[30] C. Cotman,et al. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. , 1991, European journal of pharmacology.
[31] P. Mcgeer,et al. Reactions of the Immune System in Chronic Degenerative Neurological Diseases , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[32] D. Selkoe,et al. Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease. , 1991, The American journal of pathology.
[33] P. Eikelenboom,et al. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease , 1990, Neuroscience Letters.
[34] B. Morgan. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. , 1989, The Biochemical journal.
[35] A. Campbell,et al. IMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE SCLEROSIS , 1989, Neuropathology and applied neurobiology.
[36] T. Sato,et al. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. , 1984, Japanese journal of pharmacology.
[37] R. Levine,et al. Binding reaction between the third human complement protein and small molecules. , 1981, Biochemistry.
[38] M. Pangburn,et al. Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. , 1981, Biochemistry.
[39] R. Levine,et al. Covalent binding and hemolytic activity of complement proteins. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[40] M. Thomas,et al. Evidence for presence of an internal thiolester bond in third component of human complement. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[41] R. Levine,et al. Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. , 1979, Journal of immunology.
[42] T. Poulos,et al. Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis , 1997, Nature Medicine.
[43] H. Levine. Thioflavine T interaction with amyloid β-sheet structures , 1995 .
[44] S. Barnum. Complement biosynthesis in the central nervous system. , 1995, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[45] D. Selkoe,et al. Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity. , 1993, The American journal of pathology.
[46] E. Pryzdial,et al. A reexamination of the role of magnesium in the human alternative pathway of complement. , 1986, Molecular immunology.